ANTRIABIO, INC. (OTCMKTS:ANTB) Files An 8-K Regulation FD Disclosure

ANTRIABIO, INC. (OTCMKTS:ANTB) Files An 8-K Regulation FD Disclosure
Item 8.01 Regulation FD Disclosure.

Story continues below

Name: Nevan Elam Title: Chief Executive Officer

Exhibit Index

ExhibitNo.

Description

Press Release, dated October 4, 2017*

99.2 Stipulation and Order of Dismissal dated October 4, 2017

* The following exhibit relating to Item 8.01 is intended to be furnished to, not filed with, the SEC
AntriaBio, Inc. Exhibit
EX-99.1 2 ex99_1.htm PRESS RELEASE DATED OCTOBER 4,…
To view the full exhibit click here

About ANTRIABIO, INC. (OTCMKTS:ANTB)

AntriaBio, Inc. is a biopharmaceutical company. The Company develops sustained release injectable therapies. The Company’s products include AB101 and AB301. The Company’s lead product candidate, AB101, is a microsphere formulation of PEGylated human recombinant insulin, is being developed as an extended acting basal insulin intended for once-weekly subcutaneous injection, for use alone and in combination with bolus prandial insulin or oral glucose lowering therapies, to improve glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus. It has conducted pre-clinical studies, including acute and sub-acute toxicity studies in two species, safety pharmacology, and mutagenicity/genotoxicity studies. Its product candidate, AB301, is a once-weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, the Company’s basal insulin lead product candidate. The Company is engaged in additional ongoing preclinical studies of AB301.

An ad to help with our costs